Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See ...
5 Things to Know is CNBC's Morning Squawk newsletter, a before-the-bell briefing on the most important news, trends and analysis that investors need to start their trading day. Subscribe here to ...
At close: 24 February at 4:00:01 pm GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results